Entities / Company
Ovid Therapeutics (United States).
company in New York, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 16
What's happening
Gone quiet
No new reports in 90+ days-
Ovid Therapeutics operates within the Biotechs industry.Some support1 report2 developments inside
-
Ovid Therapeutics' candidate OV329 targets GABA aminotransferase, amidst general FDA approval news for biotech stocks.Speculative1 report
-
Ovid Therapeutics sold ganaxolone royalty rights to Immedica, which subsequently acquired Ovid's IP portfolio and completed the acquisition of Marinus.Some support2 reports
-
Jeremy Levin was appointed Chairman and CEO of Ovid Therapeutics.Some support1 report
-
Ovid Therapeutics and Zura Bio Limited are noted for developing medicines in the United States.Some support1 report
-
Lucid Capital initiated Buy coverage on Ovid Therapeutics, noting that AI stocks generally offer greater upside potential.Some support1 report
No events began in the chosen period. Widen it, or reset.
History
Events by the month they beganJune 2026
6 events- Ovid Therapeutics operates within the Biotechs industry.
- Ovid Therapeutics' candidate OV329 targets GABA aminotransferase, amidst general FDA approval news for biotech stocks.
- Ovid Therapeutics sold ganaxolone royalty rights to Immedica, which subsequently acquired Ovid's IP portfolio and completed the acquisition of Marinus.
- Jeremy Levin was appointed Chairman and CEO of Ovid Therapeutics.
- Ovid Therapeutics and Zura Bio Limited are noted for developing medicines in the United States.
- Lucid Capital initiated Buy coverage on Ovid Therapeutics, noting that AI stocks generally offer greater upside potential.